新闻 | Dr.Reddys API

Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19

Hyderabad, India, July 01, 2020

Hyderabad, India, July 01, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, hereafter referred to as “Dr. Reddy’s”) announces partnering with FUJIFILM Corporation through FUJIFILM T…

Dr. Reddy’s is featured in an article of Global Pharma Insights on “Nitrosamine contamination: pharma’s re-evaluation of its supply chain”

April 2020

Dr. Reddy’s statement on the COVID-19 pandemic

Certificate of Suitability (CEP) granted for Levofloxacin Hemihydrate

Certificate of Suitability (CEP) for the API Levofloxacin Hemihydrate has been granted.

Dr. Reddy’s is among the first companies to receive the CEP from the European Directorate for the Quality of Medicines (EDQM). Together with our expand…

US DMF for Apalutamide - Now available

Dr. Reddy’s has filed the US DMF for Apalutamide, which expands our oncology API portfolio further and demonstrates our strength in R&D and regulatory affairs.

Our API partners now have access to the US DMF and validated batch samples.…

Dr. Reddy's Sustainability Report 2018-19

Dr. Reddy's API Team moves into its new office in China

December 2019

Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019